• China approves Roche’s lung cancer drug Alecensa pharmaceutical
    August 23, 2018
    Roche’s Alecensa (alectinib) drug has secured marketing authorisation from the China National Drug Administration (CNDA) to treat advanced non-small cell lung cancer (NSCLC).
PharmaSources Customer Service